{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:46:46Z","timestamp":1747198006101,"version":"3.40.5"},"reference-count":7,"publisher":"Walter de Gruyter GmbH","issue":"12","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.1515\/cclm-2024-0742","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T08:41:05Z","timestamp":1721292065000},"page":"e255-e256","source":"Crossref","is-referenced-by-count":1,"title":["Is uracil enough for effective pre-emptive DPD testing?"],"prefix":"10.1515","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-8989","authenticated-orcid":false,"given":"Niels","family":"Heersche","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry , Erasmus University Medical Center , Rotterdam , The Netherlands"},{"name":"Department of Medical Oncology , Erasmus MC Cancer Institute, Erasmus University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Matic","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry , Erasmus University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Erasmus MC Cancer Institute, Erasmus University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke J.H.","family":"Coenen","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry , Erasmus University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.N.","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry , Erasmus University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"2024101207143203641_j_cclm-2024-0742_ref_001","doi-asserted-by":"crossref","unstructured":"Launay, M, Raymond, L, Guitton, J, Loriot, MA, Chatelut, E, Haufroid, V, et al.. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis. Clin Chem Lab Med 2024;62:2415\u201324. https:\/\/doi.org\/10.1515\/cclm-2024-0317.","DOI":"10.1515\/cclm-2024-0317"},{"key":"2024101207143203641_j_cclm-2024-0742_ref_002","doi-asserted-by":"crossref","unstructured":"Meulendijks, D, Henricks, LM, Sonke, GS, Deenen, MJ, Froehlich, TK, Amstutz, U, et al.. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:1639\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(15)00286-7.","DOI":"10.1016\/S1470-2045(15)00286-7"},{"key":"2024101207143203641_j_cclm-2024-0742_ref_003","doi-asserted-by":"crossref","unstructured":"Henricks, LM, Lunenburg, CATC, de Man, FM, Meulendijks, D, Frederix, GWJ, Kienhuis, E, et al.. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:1459\u201367. https:\/\/doi.org\/10.1016\/s1470-2045(18)30686-7.","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"2024101207143203641_j_cclm-2024-0742_ref_004","doi-asserted-by":"crossref","unstructured":"Thomas, F, Hennebelle, I, Delmas, C, Lochon, I, Dhelens, C, Garnier Tixidre, C, et al.. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil\/uracil ratio. Clin Pharmacol Ther 2016;99:235\u201342. https:\/\/doi.org\/10.1002\/cpt.210.","DOI":"10.1002\/cpt.210"},{"key":"2024101207143203641_j_cclm-2024-0742_ref_005","doi-asserted-by":"crossref","unstructured":"Henricks, LM, Kienhuis, E, de Man, FM, van der Veldt, AAM, Hamberg, P, van Kuilenburg, ABP, et al.. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose capecitabine. JCO Precis Oncol 2017;1:1\u201310. https:\/\/doi.org\/10.1200\/po.17.00118.","DOI":"10.1200\/PO.17.00118"},{"key":"2024101207143203641_j_cclm-2024-0742_ref_006","doi-asserted-by":"crossref","unstructured":"Henricks, LM, Siemerink, EJM, Rosing, H, Meijer, J, Goorden, SMI, Polstra, AM, et al.. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer 2018;142:424\u201330. https:\/\/doi.org\/10.1002\/ijc.31065.","DOI":"10.1002\/ijc.31065"},{"key":"2024101207143203641_j_cclm-2024-0742_ref_007","doi-asserted-by":"crossref","unstructured":"Etienne-Grimaldi, MC, Pallet, N, Boige, V, Ciccolini, J, Chouchana, L, Barin-Le Guellec, C, et al.. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer 2023;181:3\u201317. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028.","DOI":"10.1016\/j.ejca.2022.11.028"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0742\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T07:16:20Z","timestamp":1728717380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0742\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":7,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2024,11,26]]}},"alternative-id":["10.1515\/cclm-2024-0742"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2024-0742","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2024,7,19]]}}}